WallStreetZenWallStreetZen

NASDAQ: BFRI
Biofrontera Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their BFRI stock forecasts and price targets.

Forecast return on equity

Is BFRI forecast to generate an efficient return?

Company
N/A
Industry
35.36%
Market
216.29%

Forecast return on assets

Is BFRI forecast to generate an efficient return on assets?

Company
N/A
Industry
19.03%

BFRI earnings per share forecast

What is BFRI's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.13
Avg 2 year Forecast
$0.14

BFRI revenue forecast

What is BFRI's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$46.1M+24.1%
Avg 2 year Forecast
$54.7M+47.31%
Avg 3 year Forecast
$61.6M+65.69%
BFRI's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BFRI revenue growth forecast

How is BFRI forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
18.53%
Industry
36.02%
Market
22.81%
BFRI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BFRI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BFRI vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
BFRI$0.89N/AN/A
BGM$1.48N/AN/A
GELS$0.86N/AN/A
YCBD$0.94$2.00+112.77%Strong Buy
CABR$0.96N/AN/A
View Top Pharmaceutical Stocks

Biofrontera Stock Forecast FAQ

What is BFRI's earnings growth forecast for 2026-2027?

(NASDAQ: BFRI) Biofrontera's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 51.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.92%.

Biofrontera's earnings in 2026 is -$17,572,000.On average, 4 Wall Street analysts forecast BFRI's earnings for 2026 to be -$1,544,568, with the lowest BFRI earnings forecast at -$2,625,532, and the highest BFRI earnings forecast at -$366,922.

In 2027, BFRI is forecast to generate $1,663,381 in earnings, with the lowest earnings forecast at $1,598,150 and the highest earnings forecast at $1,712,303.

If you're new to stock investing, here's how to buy Biofrontera stock.

What is BFRI's revenue growth forecast for 2026-2028?

(NASDAQ: BFRI) Biofrontera's forecast annual revenue growth rate of 18.53% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 36.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.

Biofrontera's revenue in 2026 is $37,165,000.On average, 4 Wall Street analysts forecast BFRI's revenue for 2026 to be $537,220,657, with the lowest BFRI revenue forecast at $503,417,223, and the highest BFRI revenue forecast at $566,679,266. On average, 3 Wall Street analysts forecast BFRI's revenue for 2027 to be $637,710,739, with the lowest BFRI revenue forecast at $612,713,438, and the highest BFRI revenue forecast at $656,476,188.

In 2028, BFRI is forecast to generate $717,292,082 in revenue, with the lowest revenue forecast at $689,173,030 and the highest revenue forecast at $738,398,843.

What is BFRI's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BFRI) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 19.03%.

What is BFRI's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: BFRI) Biofrontera's current Earnings Per Share (EPS) is -$1.49. On average, analysts forecast that BFRI's EPS will be -$0.13 for 2026, with the lowest EPS forecast at -$0.23, and the highest EPS forecast at -$0.03. In 2027, BFRI's EPS is forecast to hit $0.14 (min: $0.14, max: $0.15).

What is BFRI's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BFRI) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.